AIMSTM enables an innovative biomarker led drug pipeline
Focusing on emerging drug targets, Protai's AIMSTM platform paves the way to a unique precision medicine approach, facilitating an accelerated drug development process
PRT-001 (USP1)
PRT-002 (KAT6A/B)
PRT-003 (Undisclosed)
Multiple programs under evaluation
STAGE
Early Discovery
Preclinical
IND Enabling
Drug
Biomarker
Collaborate with us
Get in touch with us for questions and potential collaborations.
